The FDA Report on Intraocular Lenses

Walter J. Stark, David M. Worthen, Jack T. Holladay, Patricia E. Bath, Mary E. Jacobs, George C. Murray, Eleanor T. McGhee, Max W. Talbott, Melvin D. Shipp, Nancy E. Thomas, Roger W. Barnes, Daniel W.C. Brown, Jorge N. Buxton, Robert D. Reinecke, Chang Sheng Lao, Scarlett Fisher

Research output: Contribution to journalArticlepeer-review

167 Scopus citations


Clinical studies of intraocular lenses (IOLs) as investigational devices have been regulated in the United States by the Food and Drug Administration (FDA) since February 9, 1978. As of August 1982, data have been collected on more than one million IOLs implanted. During the last 12 months of the study, 409,000 IOLs were implanted. Visual acuity of 20/40 or better at one year after surgery was present in 85% of over 45,000 cases reviewed. Increasing patient age, surgical problems, postoperative complications, and adverse reactions were factors that reduced the visual acuity. The current trend in the USA is for implantation of the posterior chamber and anterior chamber IOLs.

Original languageEnglish (US)
Pages (from-to)311-317
Number of pages7
Issue number4
StatePublished - 1983
Externally publishedYes


  • U.S. Food and Drug Administration (FDA)
  • cataract
  • intraocular lenses
  • pseudophakos

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'The FDA Report on Intraocular Lenses'. Together they form a unique fingerprint.

Cite this